Pyridostigmine Bromide
19 NDCs across 13 manufacturers|16 Generic,3 Brand
Pyridostigmine Bromide is used to treat drug-induced abnormalities and myasthenia gravis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Nov 27, 1990. FDA's Orange Book lists 10 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $38 million on Pyridostigmine Bromide across 278,000 claims for 67,000 beneficiaries.
Pyridostigmine Bromide is available as 19 NDCs from 13 manufacturers (16 generic, 3 brand), with NADAC prices from $0.26 to $39.34 per EA — the most expensive product costs about 153× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
19
16G / 3B
Manufacturers
13
competing in market
Price Spread
$0.26 – $39.34
per EA, 13 of 19 NDCs
7d Activity
avg +2.5% WoW · of 19 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
13 manufacturers producing PYRIDOSTIGMINE BROMIDE(2 pricing outliers)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
MESTINON 180 MG TIMESPAN | $39.3384 per EA | — |
MESTINON 60 MG TABLET | $20.7334 per EA | — |
PYRIDOSTIGMINE BR 30 MG TABLET | $6.9510 per EA | -0.06% |
PYRIDOSTIGMINE ER 180 MG TAB | $5.1534 per EA | — |
PYRIDOSTIGMINE ER 180 MG TAB | $4.2944 per EA | -2.77% |
PYRIDOSTIGMINE ER 180 MG TAB | $4.2944 per EA | -2.77% |
MESTINON 60 MG/5 ML SYRUP | $1.9930 per ML | — |
PYRIDOSTIGMINE 60 MG/5 ML SOLN | $0.8421 per ML | — |
PYRIDOSTIGMINE 60 MG/5 ML SOLN | $0.5080 per ML | +11.12% |
PYRIDOSTIGMINE 60 MG/5 ML SOLN | $0.5080 per ML | +11.12% |
PYRIDOSTIGMINE 60 MG/5 ML SOLN | $0.5080 per ML | +11.12% |
PYRIDOSTIGMINE 60 MG/5 ML SOLN | $0.5080 per ML | +11.12% |
PYRIDOSTIGMINE BR 60 MG TABLET | $0.3756 per EA | — |
PYRIDOSTIGMINE BR 60 MG TABLET | $0.2649 per EA | -1.79% |
PYRIDOSTIGMINE BR 60 MG TABLET | $0.2649 per EA | -1.79% |
PYRIDOSTIGMINE BR 60 MG TABLET | $0.2649 per EA | -1.79% |
PYRIDOSTIGMINE BR 60 MG TABLET | $0.2649 per EA | -1.79% |
PYRIDOSTIGMINE BR 60 MG TABLET | $0.2649 per EA | -1.79% |
PYRIDOSTIGMINE BR 60 MG TABLET | $0.2566 per EA | — |
Frequently Asked Questions
What is Pyridostigmine Bromide used to treat?
Pyridostigmine Bromide is used to treat drug-induced abnormalities and myasthenia gravis, per the National Library of Medicine's MED-RT classification.
When did Pyridostigmine Bromide become available as a generic?
FDA approved the first generic Pyridostigmine Bromide (ANDA) on Nov 27, 1990. The Orange Book currently lists 10 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Pyridostigmine Bromide?
In 2024, Medicare Part D spent $38 million on Pyridostigmine Bromide across 278,000 claims for 67,000 beneficiaries.
How many Pyridostigmine Bromide products are on the market?
The Pyridostigmine Bromide drug market contains 19 NDCs from 13 manufacturers — 16 generic and 3 brand products.
What is the price range for Pyridostigmine Bromide?
NADAC reference prices for Pyridostigmine Bromide range from $0.2566 to $39.3384 per EA — the most expensive product costs about 153× the cheapest. 6 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Pyridostigmine Bromide cheaper than brand?
The average generic NADAC for Pyridostigmine Bromide is $2.0591 per EA, versus $30.0359 for brand-labeled products — brand versions average about 15× the generic price.
Which manufacturers make Pyridostigmine Bromide?
13 manufacturers list Pyridostigmine Bromide in NADAC. Ranked by number of NDCs, the largest are Bausch Health US LLC (3), Oceanside Pharmaceuticals (3), Rising Pharma Holdings Inc. (2), Zydus Pharmaceuticals (USA) Inc. (2), Method Pharmaceuticals LLC (1).
How has the price of Pyridostigmine Bromide changed recently?
Over the past 7 days, 4 Pyridostigmine Bromide NDCs rose and 8 fell, with a market-wide average change of +2.5%.